BMRN — Biomarin Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual income statement for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	C2022 December 31st	C2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,846	2,096	2,419	2,854	3,221
Cost of Revenue
Gross Profit	1,376	1,593	1,887	2,274	2,623
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,929	1,935	2,233	2,370	2,812
Operating Profit	-82.3	161	186	484	409
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-75.3	150	189	542	482
Provision for Income Taxes
Net Income After Taxes	-68	142	168	427	349
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-64.1	142	168	427	349
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-64.1	142	168	434	356
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.372	0.208	0.875	2.55	3.5